ReviewEuropean respiratory review : an official journal of the European Respiratory Society2020
Clinical phenotyping: role in treatment decisions in sarcoidosis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Sarcoidosis: A Clinical Trials Perspective.Pulmonary therapy · 2026Review
- Treatable traits approach for personalised management of sarcoidosis.BMJ open respiratory research · 2026Review
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Demographic and Physiological Differences Between Fibrotic and Nonfibrotic CT Subtypes of Sarcoidosis.Chest · 2026Article
- Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Sarcoidosis.Tuberculosis and respiratory diseases · 2025Article
- Phenotyping sarcoidosis: a single institution retrospective analysis.Frontiers in medicine · 2025Article
- [Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].Wiener klinische Wochenschrift · 2024Article
- Phenotypes and Serum Biomarkers in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2024Review
- Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation.Immunity · 2023Article
- Treat to target and tight control: Could be a new approach in the treatment of sarcoidosis?Intractable & rare diseases research · 2023Review
- Investigating the treatment phenotypes of cardiac sarcoidosis: A prospective cohort study.American heart journal plus : cardiology research and practice · 2022Article
- Clinical, imaging and functional determinants of sarcoidosis phenotypes in a Greek population.Journal of thoracic disease · 2022Article
- Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches.Frontiers in medicine · 2022Review
- State-of-the-Art Treatments for Sarcoidosis.Methodist DeBakey cardiovascular journal · 2022Review
- Rare case of multisystem sarcoidosis.BMJ case reports · 2021Article
- Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT.Frontiers in medicine · 2021Article
- Clinical phenotyping in sarcoidosis management.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021Article
- CT Findings in Pulmonary and Abdominal Sarcoidosis. Implications for Diagnosis and Classification.Journal of clinical medicine · 2020Review
- Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Sarcoidosis Phenotypes.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A variety of phenotypic categorisations have been developed for sarcoidosis. Phenotyping has been used for genetics studies and to guide treatment selection. The authors participated in a Delphi expert consensus panel to develop a proposed phenotype categorisation and treatment recommendations for pulmonary sarcoidosis patients. Panellists reached consensus that asymptomatic patients with normal pulmonary function and adenopathy alone or normal chest imaging do not require therapy, while symptomatic patients with impaired pulmonary function or infiltrates should be treated. The panel did not reach consensus on asymptomatic patients with abnormal chest imaging or reduced pulmonary function, or symptomatic patients with normal chest imaging and pulmonary function. The proposed phenotype categories and associated treatment recommendations are asymptomatic (no therapy), acute (disease duration <1-2 years, apparently self-limited, corticosteroids), chronic (antimetabolites and other second-line therapies) and advanced (biologics). Some clinical settings, such as dyspnoea/hypoxaemia at rest, severely impaired or rapidly decreasing pulmonary function tests, and severe cardiac, neurologic, ocular or renal involvement warrant immediate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.